Recent HIV-VL clinical research initiatives in East-Africa

Johan van Griensven
Institute of Tropical Medicine, Antwerp
Barcelona, October 4
VL-HIV coinfection

- Limited concerted clinical research activities on VL/HIV in East-Africa
- Research collaboration
  - DNDi/LEAP
  - MSF
  - Addis Abeba University
  - Gondar University
  - ITM-Antwerp
Acknowledgements

- Asrat Hailu (Addis Ababa University)
- Ermias Diro (Gondar University, PhD-student)
- Koert Ritmeijer (MSF)
- Manica Balasegaram (DNDi)
- Ed Zijlstra (DNDi)
VL-HIV clinical research

- Secondary prophylaxis to reduce relapse rate
- RCT aiming to increase initial cure rate
- “Low hanging fruits”: HIV-1 PIs
- Perspectives
Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study

Partners: MSF, AAU, GU, DNDi/LEAP, ITM-A

Legal sponsor: ITM-A
Secondary prophylaxis: zoonotic transmission

- “Secondary prophylaxis is recommended, particularly when CD4+ counts <200 cells/μL (AII)”

- “Existing data are insufficient to recommend a specific regimen” – Centers for Disease Control (CDC)
WHO: anthroponotic transmission

- “In anthroponotic VL, the risk of resistance development means that HIV-coinfected patients may become an important reservoir of drug-resistant *L. donovani*. “WHO

- ‘Drugs used to treat relapse should therefore be avoided for secondary prophylaxis’” WHO

Fifth Consultative Meeting on *Leishmania*/HIV Coinfection
Options for secondary prophylaxis

Antimonials

Amphotericin B lipid formulations

Pentamidine

USED FOR TREATMENT

NOT USED REGISTERED FOR VL in Ethiopia DONATION (Sanofi)
Pentamidine secondary prophylaxis

- Pentamidine secondary prophylaxis (PSP) used in high-income countries (monthly)
  - Safety issues as treatment (daily)
  - Prophylactic use: limited toxicity (monthly)
- Operational challenges and issues when implementing in Ethiopian health-care system
  - Safe?
  - Feasible?
  - Effectiveness?
Study design

- No documented experience implementing in remote areas – E-African context
  - Pilot project with need of careful documentation
    - Safety, feasibility and effectiveness
  - Inform policy and guidelines

"Recommended intervention": no placebo
No alternative: no comparator
Pentamidine 4 mg/kg iv (im)/60 min

Monthly PSP 12M
Evaluation for safety/relapse

Multicentric prospective cohort (GoU – Abderafi)

Exclusion criteria:
Renal, cardiac dysfunction,
Diabetes,
Pregnancy/lactation

Start October 2011 – 4 years

Main analysis: 12M data

72 adults with VL/HIV
High relapse risk: any of
- relapse
- CD4<200 cells/µL
- WHO stage IV
Negative TOC

CD4<200

(PSP – 6M)

Extended FU 12M
Relapse (rebound?)
Long-term toxicity
VL-HIV clinical research

- Secondary prophylaxis to reduce relapse rate
- RCT aiming to increase initial cure rate
A randomized trial of AmBisome® monotherapy and combination of AmBisome® and miltefosine in patients with visceral leishmaniasis co-infected with HIV in Ethiopia

Partners: AAU, GU, DNDi, LEAP, MSF, LSHTM, ITM-A

Legal sponsor: DNDi
Antimonials
Effective but highly toxic

Miltefosine
Safe but less effective

Ambisome 30 mg/kg
Excellent tolerance, high initial failure rate

COMBINATION THERAPY
Preliminary data

AMBISOME 40 mg/kg
FDA/Mediterranean/WHO
Objectives

■ **Overall objective**
  - To identify a safe and effective treatment for VL in VL/HIV coinfected pts in Ethiopia

■ **Primary Objective:**
  - To evaluate the end of treatment efficacy of a AmBisome® + miltefosine and AmBisome® monotherapy in high dose

■ **Secondary Objectives:**
  - To evaluate survival at 12 months
  - To assess safety of the regimens
Study design

Primary VL + HIV coinfectected patients
5-60 years

Exclusion if child bearing potential, TB

Randomization

Ambisome high dose
Ambisome 40 mg/kg - 24d
(8x5mg/kg)

Combination therapy
Ambisome 30 mg/kg - 11d
(6x5mg/kg)
Miltefosine 150 mg - 28 d

Open-label
Proof of concept

Group sequential design (2x63 max)

Primary end-point:
End of treatment cure

Secondary end-point:
VL-free survival - 12M
Safety
HIV-1 Protease inhibitors

Evidence overview of antileishmanial effects - potential for VL/HIV coinfection
HIV-1 protease inhibitors

- Pillar of combination therapy
- Currently 10 PIs approved by FDA (>1995)
- Lopinavir/ritonavir
  - Extensive clinical experience/evaluation
  - Second-line ARV treatment (WHO)
  - Widely available in VL-endemic regions (VL/HIV)

Intracellular Survival of *Leishmania* Species That Cause Visceral Leishmaniasis Is Significantly Reduced by HIV-1 Protease Inhibitors
Effect of PIs on Leish: summary

- Inhibitory effect of HIV-1 PIs on L donovani/infantum
  - Macrophage model, including (resistant) field strains and co-infection
- Effective concentration of PIs borderline levels for clinical use
- NFV most well studied/most active
- Limited data with LPV in L infantum/donovani
  - Unpublished data: no effect
- Screening of additional PIs through DNDi
VL-HIV clinical research: perspectives

- Initial parasitological cure: findings by 2014
- Pentamidine secondary prophylaxis: by 2013
- Major knowledge gaps regarding VL/HIV
- Addressing key questions: novel therapeutic approaches + better control
  - Substudies nested in clinical trials
VL-HIV research priorities?

- Parasite: molecular, susceptibility?
- Drug: PK, ARV drug interactions
- Immunological
- Prevention of overt disease
  - Asymptomatic Leish infection in HIV+ pts
  - Natural” evolution of *L. donovani* co-infection
    - Early start of ART
    - Primary prophylaxis
VL-HIV clinical research: perspectives

- VL/HIV clinical research consortium or partnership?
  - Join forces/complementary expertise
  - Funding
  - Applied/clinical and basic research

- International linkage
  - Multi-regional studies
  - Exchanges of knowledge, expertise
  - Pro-active reflection on how to maximally exploit studies at the global level
Thank you